ArticleAdvanced healthcare materials2026
Engineering Volumetric Tissue Analogs via Assembly of Endothelial Cell-Covered Spheroidal Microtissues.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Challenges and opportunities in generating microvasculature using bioprinting techniques.npj biomedical innovations · 2026Review
- Bioprinting and assembly of organ building blocks for tissue engineering applications.Materials today. Bio · 2026Article
- Engineering Volumetric Tissue Analogs via Assembly of Endothelial Cell-Covered Spheroidal Microtissues.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tissue engineering holds a significant promise for the development of bioartificial organs applicable to transplantation. However, the size of engineered tissues remains limited, primarily due to the challenge of establishing microvascular networks within tissue constructs. In this study, engineered tissues are fabricated and embedded with functional microvascular networks by assembling endothelial cell-covered spheroidal microtissues. Utilizing a preset extrusion bioprinting and microfluidic emulsification approach, spheroidal microtissues covered with endothelial cells are successfully fabricated, demonstrating high structural integrity compared with non-structured spheroidal microtissues. Upon assembling endothelial cell-covered microtissues, vascularized tissue structures are generated. Additionally, perfusion of the culture medium through the tissue structure created by microtissue assembly preserves the intermicrotissue spaces, which can be considered vascular channels, facilitating the development of highly vascularized tissues. By controlling the medium perfusion rate, volumetric functional tissues are produced that can be cultured for 7 days in vitro. This innovative technique for fabricating highly vascularized volumetric tissues holds potential as a foundational technology for producing artificial organs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.